By Dale Wannen
With the close of 2016 approaching, it’s that time again where we can sit back and think about what an “interesting” year it has been. In fact, just the news of Brexit and the rather surprising election results would have been plenty to sit and ponder over some spiked egg nog. But if you still have an appetite, check out our naughty and nice corporate scandals to bring lively conversation to the holiday party.
2. Increasing the price of a service or good by over 600 percent would generally cause the buyer to simply stop buying. But when the convoluted world of pharmaceuticals is involved, it seems to be the norm. Enter the Epipen and Mylan Pharmaceutical CEO Heather Bresch. As Bresch spiked the cost of the EpiPen, which is used to help children who experience allergic reactions, her own compensation increased 671 percent -- from about $2.5 million in 2007, to some $18.9 million in 2015. Mylan agreed to fork over $465 million to make up for years of underpaid Medicaid rebates on the product. The company is also in the midst of laying off about 10 percent of its workforce.
3. Got a friend at JPMorgan? JPMorgan Chase & Co. will pay $264 million to the U.S. government to settle allegations that it hired the children and relatives of influential Chinese policymakers in the hope of winning their business. The settlement follows a three-year investigation. The practice of giving the children of China's ruling class plum jobs was so common that the bank had a formal program known as "Sons and Daughters." The program included spreadsheets that tracked how often the hires turned into business deals. Somehow CEO Jamie Dimon still has a job and is now a member of President-elect Donald Trump’s economic advisory team.
4. The big pharmas sure know how to pay themselves. This final spot goes to Leonard Schleifer of Regeneron Pharmaceuticals. He netted about $47 million, up from $42 million last year. To put that in perspective: With a five-day, 40-hour work week, Schleifer would make more than $22,800 an hour; $182,000 a day; and $910,000 a week. As of Dec. 19, the stock’s year-to-date performance was negative 30 percent. Yes, that’s negative. Something tells me that Regeneron’s compensation package needs some tweaking.
2. Patagonia donates all Black Friday profits to environmental charities. Can you top that!? The apparel company donated $10 million in Black Friday sales to charity. Instead of donating to just one charity, however, Patagonia will give money to "hundreds of grassroots environmental organizations." The activewear company only projected $2 million in sales and said it was "humbled" by the final figure. Patagonia is not a publicly-traded stock. Shucks.
3. Take that United States! At 648 megawatts, India and the Adani Group have opened the largest solar plant in the world. The plant will power 150,000 homes and is a step closer to making the country fully sustainable. Facing a growing population, India’s goal is to produce 40 percent of its energy through renewable resources by 2030. The world's second largest solar plant, the Topaz Solar Farm in San Luis Obispo County, California, has a capacity of 550 megawatts. Do I sense a little friendly alternative energy competition to build the first 1,000-megawatt station?
4. How about a positive note for the big pharmas? Fortune Magazine unveiled its 2016 “Change the World” roster of 50 companies which focused on social and environmental challenges. Topping the list is pharma firm GlaxoSmithKline, which bases drug prices on income levels in the countries where it operates and reinvests 20 percent of any profits it makes in the least developed countries into training health workers and building medical infrastructure. On top of this, its CEO made a fraction of what the aforementioned drug-pushing CEOs made.
Image credit: Flickr/Mobilus In Mobili
Dale Wannen is President of Sustainvest Asset Management, an investment advisory firm focused on sustainable and responsible investing (SRI).